Lerociclib not checked
Genor Biopharma · G1T38 · GB491
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
- How it’s given
- “Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)”In the company’s words, NCT05851014 on ClinicalTrials.gov
- Tested for
- Breast Cancer
- Main trialPhase 3
- “The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy”In the company’s words, NCT05851014 on ClinicalTrials.gov
- Other names
- G1T38 · GB491 · test drug + Fulvestrant
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jan 2026 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | |
| Phase 3Completed | 2 Dec 2022 | GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer | |
| Phase 3Withdrawn | Mar 2024 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | |
| Phase 2Terminated | 29 Nov 2023 | A Study of Lerociclib in Participants With Advanced Breast Cancer | |
| Phase 1/2Completed | 14 Dec 2021 | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | |
| Phase 1/2Unknown | Jun 2023 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | |
| Phase 1Completed | 14 Nov 2022 | A Study of [14C]GB491 in Male Healthy Subjects | |
| Phase 1Unknown | 12 Dec 2023 | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026